



April 22, 2020  
JCR Pharmaceuticals Co., Ltd.

Translation

### Notice Regarding Change of Directors and Nomination of Candidates for New Members of the Board of Directors

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that its Board of Directors resolved at a meeting held today to submit a proposal regarding the change of Directors and nomination of candidates for the Board of Directors to be presented before JCR’s Ordinary General Meeting of Shareholders scheduled in June, 2020. The change of Directors and appointment of the new Members of the Board will be subject to approval at the Ordinary General Meeting of Shareholders.

#### 1. Promoting Director

Vice President Toru Ashida (Current Senior Executive Director)

#### 2. Candidates for New Directors

Name (Date of birth)	Hiroyuki Sonoda, Ph.D. (June 15, 1978)
Career	Apr. 2003 JCR Pharmaceuticals Co., Ltd. Apr. 2016 Director, Corporate Planning Division (Research) Oct. 2017 Leader, Frontier Research Unit Apr. 2018 Executive Director, Research Planning Division (current) Jun. 2018 Corporate Officer (current)

Name (Date of birth)	Mathias Schmidt, PD, Ph.D. (February 13, 1968)
Career	2001 Laboratory Head and Senior Group Leader Oncology Altana Pharma AG and Nycomed GmbH (Germany) 2003 Lecturer in Disease Biology, Pharmacology, Human Biology, Drug Discovery & Development, University of Constance, (Germany). (current) Jan. 2010 Principal & Head of Biologics Department, Nycomed GmbH (Germany) (now Takeda GmbH). Jun. 2012 Vice President Biological Sciences Takeda California (USA). Oct. 2016 President and Chief Executive Officer, ArmaGen, Inc. (USA) (current) Mar. 2019 Executive Vice President, Head of Research and Development, Triphase Accelerator Corporation (USA). (current)

### 3. Retiring Director

Yuji Sato, M.D., Ph.D. (Current Vice President)

Mr. Sato will be appointed “Executive Fellow” at a Board Meeting as scheduled on June, 2020.

Mamoru Morita (Current Senior Executive Director)

Mr. Morita will be appointed “Senior Advisor” at a Board Meeting as scheduled on June, 2020.

#### <Reference>

Members of the Board of Internal Directors (Planned after a Board Meeting on June 24, 2020)

Title	Name	Areas of responsibility ・ Concurrent position
Representative Director and Chairman, President & CEO	Shin Ashida	-
Representative Director and Senior Vice President	Hiroshi Yoshimoto	In charge of Production Executive Manager, Production Division
Vice President	Toru Ashida	Executive Director, Sales Division In charge of Corporate Strategy
Senior Executive Director	Hiroyuki Sonoda, Ph.D. (new)	In charge of Research and Development
Senior Executive Director	Mathias Schmidt, PD, Ph.D. (new)	In charge of Overseas Strategy CEO, ArmaGen, Inc.

### **[About JCR Pharmaceuticals]**

JCR is a specialty pharma company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, “Contributing towards people’s healthcare through pharmaceutical products” drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations

### **[Cautionary Statement Regarding Forward-Looking Statements]**

*This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.*

*This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.*

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jcrpharm.co.jp](mailto:ir-info@jcrpharm.co.jp)

END

###